Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:33 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 4,560 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: assessment only control Clear all

Conditions: Cystic Fibrosis-related Diabetes, Cystic Fibrosis Pulmonary Exacerbation, Cystic Fibrosis in Children
Interventions: Sensor Augmented Pump Therapy, Standard of Care with CGM; Device
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 8 Years to 25 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Type 2 Diabetes Mellitus
Interventions: Sotagliflozin (SAR439954), Placebo, Metformin, Sulfonylurea; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 507 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 28
States / cities: Litchfield Park, Arizona • Peoria, Arizona • Greenbrae, California + 25 more

Conditions: Epilepsy
Interventions: OPC-214870, Placebo; Drug · Other
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Ormond Beach, Florida

Conditions: Healthy Volunteers
Interventions: AZD2373 subcutaneous injection, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Hypercholesterolemia
Interventions: LIB003; Biological
Lead sponsor: LIB Therapeutics LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Healthy Volunteer
Interventions: Placebo, PF-04958242; Drug
Lead sponsor: Biogen; Industry
Eligibility: 21 Years to 55 Years
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: New Haven, Connecticut

Conditions: Hoarding Disorder
Interventions: Acceptance and Commitment Therapy Bibliotherapy; Behavioral
Lead sponsor: Utah State University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Syracuse, New York • Logan, Utah

Conditions: Knee Osteoarthritis
Interventions: PTP-01, Placebo control / saline vehicle; Biological · Other
Lead sponsor: Doron Therapeutics Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 9
States / cities: Birmingham, Alabama • Tucson, Arizona • La Mesa, California + 6 more

Conditions: Spinal Cord Injuries (Complete and Incomplete), Spinal Cord Injury, Spinal Cord Injury Cervical, Spinal Cord Injury Thoracic, Spinal Cord Injuries, Spasticity, Spasm, Muscle Spasticity, Muscle Hypertonia, Muscle Spasm
Interventions: Transcutaneous spinal stimulation at 30 Hz, Transcutaneous spinal stimulation at 75 Hz, Tizanidine, Baclofen, Placebo; Other · Drug
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Jackson, Mississippi

Conditions: Esophageal Stricture
Interventions: Budesonide; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Mouth Abnormalities, Cleft Palate, Birth Defect
Interventions: Ropivacaine, Sham Comparator; Drug · Other
Lead sponsor: University of Florida; Other
Eligibility: 3 Months to 5 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Ocular Hypertension, Primary Open Angle Glaucoma
Interventions: AKB-9778 Ophthalmic Solution, Placebo Ophthalmic Solution; Drug
Lead sponsor: Aerpio Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 91 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 2
States / cities: Austin, Texas • Dallas, Texas

Conditions: Anaemia
Interventions: Daprodustat tablets, Matching placebo tablets, Epoetin alfa vials, Saline vials or bags; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 407 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 23
States / cities: Mesa, Arizona • Fresno, California • Los Angeles, California + 19 more

Conditions: Zika
Interventions: Zika Virus Purified Inactivated Vaccine, Placebo; Biological · Other
Lead sponsor: Kathryn Stephenson; Other
Eligibility: 18 Years to 50 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Labor Pain
Interventions: Ultrasound, Palpation; Device · Other
Lead sponsor: Thomas J. Vernon; Other
Eligibility: 18 Years and older · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Diabetes Mellitus, Type 2
Interventions: PF-05175157 or Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: South Miami, Florida

Conditions: Asthma
Interventions: PF-04191834, zileuton, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 4
States / cities: Baltimore, Maryland • North Dartmouth, Massachusetts • Kalamazoo, Michigan + 1 more

Conditions: Thyroid; Functional Disturbance
Interventions: Erythrosine, prepared in drinking water (0.69 mg/kg bw/day), SODIS-treated erythrosine, prepared in drinking water (0.69 mg/kg bw/day), Iodine, prepared in drinking water 0.075 mg/kg bw/day); Dietary Supplement
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Proliferative Diabetic Retinopathy
Interventions: emixustat hydrochloride, Placebo; Drug · Other
Lead sponsor: Kubota Vision Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Arcadia, California

Conditions: Marijuana Use
Interventions: 1) Face-to-face, and 2) Computer-mediated motivational type interviews; Behavioral
Lead sponsor: University of Texas, El Paso; Other
Eligibility: 18 Years to 29 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: El Paso, Texas

Conditions: Gout
Interventions: RDEA3170 and Placebo; Drug
Lead sponsor: Ardea Biosciences, Inc.; Industry
Eligibility: 20 Years to 55 Years · Male only
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy Subjects
Interventions: AZD1979, Placebo to match; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Heart Failure
Interventions: HeartNet Ventricular Support System, Optimal Medical/Device Therapy; Device · Drug
Lead sponsor: Paracor Medical, Inc; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 29
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 26 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Group-based Cognitive Behavioral Intervention, Web-based Cognitive Behavioral Intervention, Usual Care; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Atlanta, Georgia

Search by objective public record fields.

Sensor Augmented Pump (SAP) Therapy for Inpatient CFRD Management

Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin

A Single-blind, Placebo-controlled, Outpatient Trial to Assess the Effects of Single Oral Tablet Dose of OPC-214870

A Study to Assess Safety, Tolerability, PK and PD of AZD2373 in Healthy Male Participants of Sub-Saharan West African Ancestry

Study to Evaluate the Safety, PK, and Pharmacodynamics of LIB003

A Study To Assess Effects Of PF-04958242 On Bold Functional Magnetic Resonance Imaging During Working Memory Activation And Arterial Spin Labeling At Rest In Healthy Subjects

A Test of Acceptance-based Bibliotherapy for Hoarding Disorder

A Study to Evaluate the Efficacy and Safey of PTP-001 (MOTYS™) in Knee Osteoarthritis Patients (MOTION-P)

Electrical Neuromodulation for Modifying Spinal Network Involved in Spasticity

Prospective Evaluation of Budesonide for Prevention of Esophageal Strictures After Endotherapy

Evaluation of Trigeminal Nerve Blockade

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AKB-9778 Ophthalmic Solution

Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Three-times Weekly Dosing in Dialysis (ASCEND-TD)

Zika Virus Purified Inactivated Vaccine (ZPIV) Accelerated Vaccination Schedule Study

Use of Ultrasound Guidance to Assist With Labor Epidural Placement in Patients With a BMI ≥40

A Study Of PF-05175157 In Healthy Volunteers

PF-04191834 Single Dose Bronchodilatory Study In Asthma.

Photodegraded Edible Food Dyes

Study to Evaluate Effects of Emixustat Hydrochloride in Subjects With Proliferative Diabetic Retinopathy

Computer-Mediated Versus Face-to-Face Motivational-Type Interviews

Single and Multiple Dose Study in Japanese Subjects

A First Time in Man Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1979 in Healthy Males

Prospective Evaluation of Elastic Restraint to LESSen the Effects of Heart Failure (PEERLESS-HF) Trial

Cognitive Behavioral Therapy for African Americans With Uncontrolled Type-2 Diabetes